- GSK China Hepatitis B Alliance Puts Bepirovirsen And Valuation In Focus
May 12, 2026
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
GSK (LSE:GSK) has entered a partnership with Sino Biopharmaceutical’s subsidiary CTTQ to launch and commercialize its hepatitis B treatment, bepirovirsen, in China. Bepirovirsen has received priority regulatory review status in China following Phase III trial results. The collaboration focuses on accelerating patient access to bepirovirsen across China’s large chronic hepatitis B population.
GSK, trading at around £18.445, has returned 37.2% over the past year and 63.6% over the past five years, while the share price is up 41.5% over three years and 0.7% year to date. In this context, this new China focused hepatitis B partnership adds another layer to the company’s efforts to build out its vaccines and specialty medicines portfolio.
For investors watching LSE:GSK, the agreement with Sino Biopharmaceutical highlights how the company is looking to expand access to newer therapies across key international markets, particularly in Asia-Pacific. The priority review status for bepirovirsen in China also puts a clear regulatory milestone on the radar that could influence how the market views GSK’s exposure to hepatitis B treatments in the region.
Stay updated on the most important news stories for GSK by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on GSK.LSE:GSK Earnings & Revenue Growth as at May 2026
4 things going right for GSK that this headline doesn't cover.
Investor Checklist: What This Partnership Means for GSK
Quick Assessment
✅ Price vs Analyst Target: At £18.445, GSK trades about 9% below the £20.30 analyst price target, so the stock sits inside the analyst range with some upside implied by consensus. ✅ Simply Wall St Valuation: GSK is flagged as undervalued, trading 59.1% below the platform's estimated fair value. ❌ Recent Momentum: The share price is down 15.2% over the last 30 days, so the short term trend has been weak.
There is only one way to know the right time to buy, sell or hold GSK. Head to Simply Wall St's company report for the latest analysis of GSK's Fair Value.
Key Considerations
📊 The Sino Biopharmaceutical partnership could strengthen GSK's reach in China for hepatitis B, which may become a more visible part of the investment story as the launch progresses. 📊 Watch the China regulatory timeline for bepirovirsen, any updates on pricing and access, and how hepatitis B revenues are discussed in future company updates. ⚠️ Existing flags around debt levels and dividend stability mean you may want to balance the China growth potential against the current risk profile.
Story Continues
Dig Deeper
For the full picture including more risks and rewards, check out the complete GSK analysis. Alternatively, you can check out the community page for GSK to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include GSK.L.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
View Comments
- Sotrovimab (Xevudy: Vir Biotechnology, GlaxoSmithKline) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
May 11, 2026
Company Logo
Key market opportunities for Sotrovimab (Xevudy) include increased prevalence of COVID-19, necessitating early-stage treatment and high-risk patient protection; rising healthcare investments supporting R&D and expanded access; strategic collaborations enhancing development; and expanding regional biologics manufacturing in response to tariffs.
Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Sotrovimab or Xevudy Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The report offers invaluable insights for strategists, marketers, and senior management seeking to navigate this rapidly expanding market. A focal point of growth, the sotrovimab or xevudy market is set to shape health and pharmaceutical trends over the next decade.
The historic growth of the Sotrovimab (Xevudy) market was driven by the emergency authorization of COVID-19 monoclonal antibodies, a high hospitalization risk during the early pandemic phases, rapid deployment of antibody therapies, and government procurement of antiviral treatments. The expansion of infusion-based treatment infrastructure further supported this growth.
Looking ahead, the market is expected to expand due to the evolution of variant-resistant antibody therapies and a growing focus on preparedness for future pandemics. Increased investment in antiviral biologics, the expansion of outpatient infusion services, and the integration of monoclonal antibodies into standard care protocols highlight major trends. This forecast period will see enhanced development of pandemic-response therapeutics and a focus on early-stage viral treatment and high-risk patient protection.
With the rising prevalence of COVID-19 cases, the market for Sotrovimab (Xevudy) is likely to experience significant growth. Factors contributing to the continuing increase in cases include the emergence of new variants, waning immunity, relaxed public health measures, and uneven vaccine coverage. Sotrovimab is effective in neutralizing the virus, reducing severe outcomes like hospitalization or death, thus providing critical support for high-risk patients.
Rising healthcare investments are expected to propel market growth by advancing research and development efforts, expanding production, and improving access through enhanced distribution networks and partnerships. For instance, the UK reported a substantial increase in total healthcare expenditure from 2022 to 2023, demonstrating an investment trend beneficial to the market.
Story Continues
Key advancements include a strategic collaboration between Vir Biotechnology and GlaxoSmithKline (GSK), enhancing their joint efforts in developing and commercializing Sotrovimab. This partnership aims to strengthen monoclonal antibody programs and broaden patient access.
GSK plc and Vir Biotechnology Inc. are principal entities in the Sotrovimab market. Geographically, North America held the largest market share in 2025, while Asia-Pacific is projected to be the fastest-growing region. The market covers regions like Asia-Pacific, Western Europe, North America, and others, including major countries such as the USA, Canada, China, and India.
Key Topics Covered:
1. Executive Summary
1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market
2. Sotrovimab or Xevudy Market Characteristics
2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Sotrovimab or Xevudy Market Attractiveness Scoring and Analysis
3. Sotrovimab or Xevudy Market Supply Chain Analysis
3.1. Overview of the Supply Chain and Ecosystem
3.2. List of Key Raw Materials, Resources & Suppliers
3.3. List of Major Distributors and Channel Partners
3.4. List of Major End Users
4. Global Sotrovimab or Xevudy Market Trends and Strategies
4.1. Key Technologies & Future Trends
4.2. Major Trends
5. Sotrovimab or Xevudy Market Analysis of End Use Industries
5.1. Hospitals
5.2. Specialty Clinics
5.3. Infusion Centers
5.4. Public Health Agencies
5.5. Ambulatory Care Centers
6. Sotrovimab or Xevudy Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, and Covid and Recovery on the Market
7. Global Sotrovimab or Xevudy Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
7.1. Global Sotrovimab or Xevudy PESTEL Analysis
7.2. Global Sotrovimab or Xevudy Market Size, Comparisons and Growth Rate Analysis
7.3. Global Sotrovimab or Xevudy Historic Market Size and Growth, 2020-2025, Value ($ Billion)
7.4. Global Sotrovimab or Xevudy Forecast Market Size and Growth, 2025-2030, 2035F, Value ($ Billion)
8. Global Sotrovimab or Xevudy Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Sotrovimab or Xevudy Market Segmentation
9.1. Global Sotrovimab or Xevudy Market, Segmentation by Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.2. Global Sotrovimab or Xevudy Market, Segmentation by Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.3. Global Sotrovimab or Xevudy Market, Segmentation by End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/ysz91n
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
View Comments
- Ambirix (GlaxoSmithKline) Market Research Report 2026: Epidemiology, Pipeline Analysis, Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
May 11, 2026
Company Logo
The ambirix market is driven by rising hepatitis infections, increased pediatric vaccination awareness, and growing healthcare expenditure. Opportunities lie in expanding pediatric coverage, emerging market access, and boosting hepatitis prevention. Tariffs encourage domestic production to support sustainable programs.
Dublin, May 11, 2026 (GLOBE NEWSWIRE) -- The "Ambirix Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The Ambirix market report offers comprehensive statistics, insights on global market size, regional shares, competitors, market trends, and opportunities. This report provides a complete analysis of the current and future industry landscape, aiding stakeholders in navigating the market dynamics effectively.
The Ambirix market is experiencing a significant growth trajectory due to several key factors influencing both historic and forecast periods. The historic growth has been primarily fueled by the global hepatitis burden, childhood vaccination schedules, public health immunization policies, and early combination vaccine approvals. School-based vaccination programs have also played a crucial role. In the forecast period, market expansion is driven by enhanced pediatric coverage, improved vaccine access in emerging markets, long-term immunity benefits, and strengthening public health funding. Additionally, concerted efforts towards global hepatitis elimination goals are contributing to this growth.
Several trends characterize the forecast period: the proliferation of combination vaccines, expansion of pediatric immunization programs, an increased focus on hepatitis prevention, better vaccine compliance through reduced dosage requirements, and government-backed vaccination campaigns.
The growing prevalence of hepatitis infections substantiates the market growth potential for Ambirix. Hepatitis, particularly types A and B, remains a significant global health concern due to escalating infection rates linked to poor sanitation, inadequate vaccination coverage, and increased population mobility. Ambirix, a combination vaccine targeting individuals aged 1-15, offers long-term protection through a two-dose regimen, particularly in high-risk regions. The CDC reported 17,650 new chronic hepatitis B cases in 2023 across the United States, underscoring the need for effective vaccination strategies to curb these infections.
The rise in healthcare expenditure further accelerates the Ambirix market, as financial resources are increasingly allocated towards health services that encompass vaccination initiatives. This trend supports healthcare systems by potentially lowering long-term treatment costs for hepatitis A and B through preventive measures. According to the UK's Office for National Statistics, healthcare spending saw a 5.6% nominal increase between 2022 and 2023, reflecting ongoing investments in public health infrastructure and services.
Story Continues
Increased public awareness of pediatric vaccination further bolsters the market. Public health campaigns, school-based programs, and initiatives from governments and healthcare organizations significantly contribute to raising awareness. By expanding vaccination coverage, especially in historically underserved regions, vaccines like Ambirix play a critical role in safeguarding children's health. The World Health Organization noted an increase in global HPV vaccine coverage among girls from 20% in 2022 to 27% in 2023, highlighting the impact of similar efforts in the hepatitis vaccine space.
GSK plc remains a major player in the Ambirix market. As of 2025, North America was the largest geographical market, while Asia-Pacific is anticipated to be the fastest-growing region. Various tariffs affect the market by increasing costs related to vaccine components and storage; however, these are also fostering domestic manufacturing capabilities, supporting sustainable immunization efforts.
Report Scope:
Indication: Hepatitis A; Hepatitis B Distribution Channel: Hospitals; Pharmacies; Public Health Programs End User: Pediatric; Geriatric Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada. Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa Time Series: Five years historic and ten years forecast. Data: Market size and growth ratios, GDP proportions, expenditure per capita insights. Data Segmentation: Historical and forecast data by country and region, market share analysis.
Major Trends
Growth of Combination Vaccines Expansion of Pediatric Immunization Programs Rising Focus on Hepatitis Prevention Improved Vaccine Compliance Through Fewer Doses Government Supported Vaccination Campaigns
For more information about this report visit https://www.researchandmarkets.com/r/ivje3p
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
View Comments
- Why These Four Biotech Stocks Prove That Follow-On Entries Still Pop Up In Stock Market Leaders
May 8, 2026
Truth be told, a survey of leading biotech stocks currently in the IBD 50 actually accentuates the importance of using both daily and weekly charts in the same manner as, say, the mega-cap leaders such as Sandisk, Micron Technology, and Western Digital in the data storage segment. The concept also applies to other tech leaders such as Marvell Technology in application-specific integrated circuits, and Ciena, a fiber-optic data networking company. Marvell carries a $140 billion market cap, and Ciena is valued at $76 billion.
Continue Reading
- GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View
May 8, 2026
Gilead Sciences, Inc. GILD reported first-quarter 2026 adjusted earnings per share (EPS) of $2.03, which beat the Zacks Consensus Estimate of $1.89. In the year-ago quarter, the company reported an adjusted EPS of $1.81.
The year-over-year increase was primarily driven by higher product sales and lower acquired IPR&D expenses.
Total revenues of $7 billion beat the Zacks Consensus Estimate of $6.9 billion. Revenues were up 4% year over year, driven by higher HIV, breast cancer drug Trodelvy and liver disease drug Livdelzi sales.
However, the stock is down on May 8, probably due to a reduction in annual EPS guidance for 2026 that did not impress the Wall Street.
Gilead’s shares have gained 9.2% year to date against the industry's decline of 0.2%.Zacks Investment Research
Image Source: Zacks Investment Research
HIV, Trodelvy and Livdelzi Power GILD’s Q1 Results
Total revenues comprise product sales and royalty, contract and other revenues.
Product sales increased 5% year over year to $6.9 billion. Excluding Veklury (remdesivir for COVID 19), product sales increased 8% to $6.8 billion.
HIV product sales grew 10% year over year to $5 billion, driven by higher demand. The figure beat both the Zacks Consensus Estimate and our model estimate of $4.8 billion.
Flagship HIV therapy Biktarvy’s sales increased 7% year over year to $3.4 billion, driven by higher demand and average realized price. The reported number beat both the Zacks Consensus Estimate and our model estimate of $3.3 billion.
Per GILD, Biktarvy accounts for over 52% share of the HIV treatment market in the United States.
Descovy (FTC 200 mg/TAF 25 mg) sales increased 38% year over year to $807 million, driven by higher average realized price and increased demand for HIV prevention. The reported number comfortably beat the Zacks Consensus Estimate of $632 million and our model estimate of $594 million.
Incremental sales of newly approved Yeztugo (lenacapavir) for pre-exposure prophylaxis (PrEP) also boosted HIV product sales. Yeztugo raked in sales of $166 million in the first quarter.
The Liver Disease portfolio sales, which include chronic HCV, chronic hepatitis B virus (HBV) and chronic hepatitis delta virus (HDV), increased 1% to $767 million, primarily driven by higher demand for Livdelzi for the treatment of primary biliary cholangitis (PBC), partially offset by unfavorable inventory dynamics and lower sales for HCV products.
Liver Disease portfolio sales missed the Zacks Consensus Estimate of $778 million but managed to beat our model estimate of $765 million.
Veklury sales plunged 52% to $144 million, primarily due to lower rates of COVID-19-related hospitalizations.
Story Continues
Cell Therapy product (comprising Yescarta and Tecartus) sales decreased 12% to $407 million due to ongoing competitive headwinds. The figure missed the Zacks Consensus Estimate of $432 million and our model estimate of $447 million.
Yescarta sales decreased 14% year over year to $332 million due to competition. Tecartus (adult acute lymphoblastic leukemia) sales declined 4% to $75 million due to competition.
Breast cancer drug Trodelvy’s sales increased 37% year over year to $402 million, driven by higher demand. Trodelvy's sales beat the Zacks Consensus Estimate of $367 million and our model estimate of $352 million.
GILD’s Cost Analysis
Adjusted product gross margin was 87.5%, up from 85.5% in the year-ago quarter due to the expiration of a royalty-related obligation and product mix.
Adjusted research and development expenses totaled $1.4 billion, up from $1.3 billion in the year-ago quarter. This was primarily driven by higher investment in virology clinical manufacturing, partially offset by lower oncology clinical study activity.
Adjusted SG&A expenses increased to $1.4 billion from $1.2 billion due to higher HIV promotional expenses.
Acquired IPR&D expenses amounted to $107 million, primarily related to an $80 million upfront payment for the company’s collaboration with Suzhou Genhouse Bio Co., Ltd.
As of March 31, 2026, Gilead had $8.6 billion of cash, cash equivalents and marketable debt securities, down from $10.6 billion as of Dec. 31, 2025.
GILD Updates 2026 Guidance
Gilead now expects product sales to be between $30 billion and $30.4 billion (previous guidance: $29.6-$30 billion). The Zacks Consensus Estimate for 2026 revenues is pinned at $30.15 billion.
Total product sales, excluding Veklury, are now expected to be between $29.4 billion and $29.8 billion (previous guidance: $29-$29.4 billion). Total Veklury sales are still estimated to be $600 million.
GILD now expects to report an adjusted loss per share of $1.05-$0.65. The company had earlier anticipated adjusted EPS in the range of $8.45-$8.85. The EPS guidance was reduced approximately $9.50 due to the anticipated acquired IPR&D charges of $11.5 billion as well as financing costs related to the Arcellx, Ouro Medicines and Tubulis GmbH transactions.
GILD’s Acquisition Spree
Gilead is looking for targeted acquisitions to bolster its pipeline and diversify beyond its dominant HIV franchise.
It strengthened its oncology pipeline and long-term growth prospects by acquiring Arcellx for $115 per share in cash, implying an equity value of approximately $7.8 billion, plus a contingent value right of $5 per share. This transaction centers on anitocabtagene autoleucel (anito-cel), a late-stage CAR-T therapy for relapsed or refractory multiple myeloma (R/R MM).
The FDA accepted the biologics license application for anito-cel in fourth-line-plus (R/R MM), setting a target action date of Dec. 23, 2026. A potential approval could position anito-cel as an important growth driver in Gilead’s cell therapy portfolio.
Gilead announced a definitive agreement to acquire Tubulis, a privately held clinical-stage biotechnology company focused on next-generation antibody-drug conjugates (ADCs). The acquisition includes lead candidate TUB-040, a NaPi2b-targeted topoisomerase-I inhibitor ADC currently being evaluated in a phase Ib/II study for platinum-resistant ovarian cancer and non-small cell lung cancer.
On the inflammation front, Gilead announced a definitive agreement to acquire Ouro, a private clinical-stage biotechnology company focused on T-cell engager (TCE) therapies for autoimmune diseases, strengthening its immunology pipeline. The deal adds Ouro’s lead candidate, OM336 (gamgertamig), a BCMAxCD3 TCE, to Gilead’s portfolio.
Gilead also entered into a framework agreement with Galapagos NV GLPG related to the acquisition, under which the companies will equally share the $1.675 billion upfront payment and up to $500 million in potential milestone payments. The transaction remains subject to regulatory approvals and customary closing conditions.
Galapagos expects to assume substantially all of Ouro’s operating assets and personnel.
Our Take on GILD’s Q1 Performance
Gilead’s first-quarter results were good. HIV business continues to maintain momentum, driven by solid performance of Biktarvy and Descovy, and incremental contributions from Yeztugo.
Gilead Sciences, Inc. Price, Consensus and EPS SurpriseGilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote
Following better-than-expected first-quarter results and improving market trends, Gilead raised its 2026 sales guidance for Yeztugo to $1 billion, signaling the product’s potential to achieve blockbuster status in its first full year on the market.
The FDA accepted Gilead’s new drug application for bictegravir/lenacapavir (BIC/LEN) for virologically suppressed people living with HIV under priority review, setting a target action date of Aug. 27, 2026. A potential approval of BIC/LEN will further bolster its HIV portfolio.
Driven by increased Yeztugo sales expectations and strong first-quarter HIV performance, Gilead now projects total 2026 HIV sales growth of approximately 8% year over year, up from its prior guidance of 6% issued in February. The updated outlook includes an estimated 2% headwind related to the U.S. government’s Medicaid drug pricing agreement and proposed Affordable Care Act changes.
Approval of better HIV treatments should strengthen the HIV franchise in the wake of increasing competition from the likes of GSK plc GSK.
GSK continues to grow its HIV business, driven by strong patient demand for long-acting injectable medicines (Cabenuva and Apretude) and Dovato.
Breast cancer drug Trodelvy continues to gain market share in the second-line setting. GILD has submitted two supplemental biologics license applications seeking approval of the drug for use in first-line metastatic triple-negative breast cancer patients.
A potential approval in the first-line setting (regulatory decisions are expected in the second half of 2026) will boost sales.
Gilead’s aggressive dealmaking strategy — including the acquisition of Arcellx and agreements with Ouro and Tubulis — highlights the company’s commitment to diversifying beyond its core HIV franchise into higher-growth oncology and immunology markets. While these transactions strengthen Gilead’s long-term pipeline and growth potential, the sizable upfront payments and integration-related costs are pressuring near-term profitability.
This, in turn, has prompted Gilead to lower its EPS guidance, raising investor concerns about margin pressure and the timelinerequired for these acquisitions to generate meaningful returns.
GILD’s Zacks Rank
Gilead currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
Galapagos NV (GLPG) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults
May 7, 2026
Trailer: Ty Burrell & Julie Bowen’s Mening-ItineraryTy Burrell & Julie Bowen’s Mening-Itinerary: Sharing Food, Drinks, and Tips for ParentsTy Burrell & Julie Bowen’s Mening-Itinerary: Meet Survivor and Advocate JamieTy Burrell & Julie Bowen’s Mening-Itinerary: We Love You Too, Fake Kid
On-screen parenting duo stars in new, original video highlighting relatable parenting moments, educating viewers about meningococcal disease, also known as meningitis GSK’s Ask2BSure campaign encourages parents of teens and young adults ages 16-23 years to ask their teen’s doctor about meningitis risks and vaccination The video is now available on GSK’s YouTube channel
Invest in Gold
Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase Learn More
Thor Metals Group: Best Overall Gold IRA Learn More
American Hartford Gold: #1 Precious Metals Dealer in the Nation Learn More
Powered by Money.com - Yahoo may earn commission from the links above.
PHILADELPHIA, May 07, 2026--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new campaign spokespeople, Julie Bowen and Ty Burrell, as part of its Ask2BSure public health campaign to raise awareness and encourage parents to "ask to be sure" about the risks of meningococcal disease, also known as meningitis. As part of the initiative, the duo stars in an original video titled The Mening-Itinerary, which is available now on GSK’s YouTube channel.
The Mening-Itinerary takes viewers on a journey through everyday moments of parenting teens in real-world environments—like dorms, parties, and gyms—where teens live, gather, share space, and, through certain everyday behaviors, may share the bacteria that can cause meningitis.1,2,3 Along the way, Bowen and Burrell dig deeper into meningitis risks, hear powerful stories from real-life disease survivors and their families, and uncover the questions parents may not realize they should be asking about meningitis and vaccination.
As parents of teens themselves, both Bowen and Burrell understand that staying informed is one of the best ways to advocate for their teens’ health.
Julie Bowen said: "As a proactive parent, I was surprised to learn that my own 18-year-old son hadn’t completed his meningitis B vaccination series. It was a reminder that even as a parent who tries to stay on top of things, it’s easy to miss something."
Ty Burrell said: "We are excited to bring this educational message to life, blending humor and heart in a way that is accessible to fellow parents of teens. My teen daughters are everything to me, and I hope this video encourages parents to have a conversation with their teen’s doctor about meningitis risk and vaccination."
The Ask2BSure campaign helps to educate parents about meningitis, an uncommon but serious illness that can cause permanent complications, or even death, sometimes within 24 hours.1,2,3,4,5 Amongst teens and young adults, 16- to 23-year-olds have the highest rates of meningitis.1,6 The bacteria that can cause meningitis can pass from one person to another through certain everyday activities like sharing food, drinks and utensils, kissing, and living in close quarters.7,8 About 10-15% of people who get meningitis will die,2 and 1 in 5 survivors suffer from long-term consequences, including limb amputation, brain damage, and hearing loss.2,3
Story Continues
There are different types of meningitis vaccinations, and parents may not know if their teens are vaccinated or assume they already are. Some teens may have received vaccination for meningitis groups A, C, W, and Y, but they may still be missing meningitis B vaccination.9
Cynthia Burman, Head, Pediatric, Adolescent and Pipeline Vaccines, Medical Affairs for GSK said: "Meningococcal disease is a serious and potentially life-threatening disease, and many parents may not realize that their teen could be missing vaccination. This effort plays an important part in raising awareness and helping parents make informed decisions by encouraging conversations with their teen’s healthcare provider about meningitis vaccinations and any missed doses."
This video is now available to watch on GSK’s YouTube channel and at Ask2BSure.com.
About GSK’s Ask2BSure Campaign Ask2BSure aims to educate and empower parents of teens and young adults to start meningitis conversations with their teen’s doctors and "ask to be sure" about meningitis and vaccination. Find out more at Ask2BSure.com.
About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q1 Results for 2026.
Registered in England & Wales: No. 3888792
Registered Office: 79 New Oxford Street
London
WC1A 1DG
References:
1 Centers for Disease Control and Prevention. Clinical overview of meningococcal disease. Updated March 30, 2026. https://www.cdc.gov/meningococcal/hcp/clinical/index.html. Accessed April 30, 2026.
2 Centers for Disease Control and Prevention. Meningococcal disease symptoms and complications. Updated March 6, 2026. https://www.cdc.gov/meningococcal/symptoms/index.html. Accessed April 15, 2026.
3 Centers for Disease Control and Prevention. Meningococcal disease. In: Epidemiology and Prevention of Vaccine-Preventable Diseases (The Pink Book). Chapter 14. Updated April 12, 2024. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-14-meningococcal-disease.html. Accessed April 21, 2026.
4 Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. doi:10.1016/S0140-6736(06)67932-4
5 Pelton SI. Meningococcal disease in adolescents and young adults. J Adolesc Health. 2010;46(suppl):S9-S15. doi:10.1016/j.jadohealth.2009.11.220
6 Centers for Disease Control and Prevention. Meningococcal disease surveillance and trends. Updated February 24, 2026. https://www.cdc.gov/meningococcal/php/surveillance/index.html. Accessed April 15, 2026.
7 Centers for Disease Control and Prevention. About meningococcal disease. Updated March 30, 2026. https://www.cdc.gov/meningococcal/about/index.html. Accessed April 15, 2026.
8 Mayo Clinic. Meningitis: symptoms and causes. Updated October 17, 2024. https://www.mayoclinic.org/diseases-conditions/meningitis/symptoms-causes/syc-20350508. Accessed April 15, 2026.
9 Pingali C, Yankey D, Elam-Evans LD, et al. Vaccination coverage among adolescents aged 13–17 years—National Immunization Survey–Teen, United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(30):466-472. doi:10.15585/mmwr.mm7430a1
View source version on businesswire.com: https://www.businesswire.com/news/home/20260504262982/en/
Contacts
GSK inquiries
Media:
Kathleen Quinn +1 202 603 5003 (Washington DC)
Alison Hunt +1 540 742 3391 (Washington DC)
Investor Relations:
Frannie DeFranco +1 215 751 4855 (Philadelphia)
Jeff McLaughlin +1 215 751 7002 (Philadelphia)
View Comments
- Medable CEO Michelle Longmire Featured as Guest Speaker with Leaders from Google and Mayo Clinic at Japan’s Largest Pharmaceutical Summit
May 6, 2026
Agentic AI the focus of innovation in Japan’s rapidly growing clinical research landscape
PALO ALTO, Calif., May 06, 2026--(BUSINESS WIRE)--Medable Inc., the leading technology platform for agentic AI clinical development, today announced that its CEO and co-founder, Dr. Michelle Longmire, will be one of three international guest speakers at Japan’s largest pharmaceutical conference, Ubie Pharma Summit (May 13-14, 2026). Longmire will be speaking at the fifth annual event along with Justin Chen, MD, Clinical Specialist at Google for Health, and John Halamka, MD, President of Mayo Clinic Platform.
More than 1,000 attendees gathered at the Ubie Summit 2025. This year, guests include many distinguished leaders from government and medical organizations in Japan as well as global pharmaceutical organizations such as AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly Japan, GlaxoSmithKline, Novartis, Regeneron, and more.
Japan is actively strengthening its drug development landscape to eliminate drug lag and loss, aiming for ¥3 trillion ($20+ billion) in annual R&D investment by 2030 through government- private partnerships and AI, biotech, and new modality investments. Key efforts include the Sakigake fast-track designation, conditional early approvals for rare diseases, and utilizing real-world evidence (RWE).
"It is an honor to represent my company and country at Japan’s preeminent industry event," said Medable’s Longmire. "Japan not only has a beautiful landscape but also a culture focused on innovation and modernization through advanced technology, which is exactly what we aim to bring to Japanese clinical studies with our agentic clinical development platform."
Medable's Agent Studio transforms clinical operations capacity by tackling the repetitive, compliance-driven work that slows trials down. Instead of teams manually sorting, checking, and filing tens of thousands of documents, AI agents handle these tasks automatically, validating against study context and requirements, with human-in-the-loop oversight. Medable’s AI agents are compatible with standard clinical systems, and maintain full transparency with audit trails – delivering an AI operational layer that removes workflow bottlenecks. For example, Medable's Clinical Monitoring and TMF Agents are two enterprise-grade agents that help study teams increase efficiency.
Medable executives are also speaking at various other key life sciences industry events this month including Fierce Biotech Week in Boston (May 12-14); Scope X at Bio-IT World Expo in Boston (May 18-19); Clinical Trials Technology Congress in London (May 19-20); and, American Society of Clinical Oncology (ASCO) Conference in Chicago (May 29-June 2).
Story Continues
About Medable
Medable is on a mission to get effective therapies to people faster. Its agentic digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Leader in eCOA by Everest Group, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California. Learn more at medable.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260506171135/en/
Contacts
Media Contact
Lisa Barbadora, Barbadora INK for Medable
+1 (610) 420-3413
lbarbadora@barbadoraink.com / media@medable.com
View Comments
- GSK's (LON:GSK) Performance Is Even Better Than Its Earnings Suggest
May 6, 2026
Investors were underwhelmed by the solid earnings posted by GSK plc (LON:GSK) recently. We did some digging and actually think they are being unnecessarily pessimistic.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.LSE:GSK Earnings and Revenue History May 6th 2026
How Do Unusual Items Influence Profit?
Importantly, our data indicates that GSK's profit was reduced by UK£1.9b, due to unusual items, over the last year. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. Assuming those unusual expenses don't come up again, we'd therefore expect GSK to produce a higher profit next year, all else being equal.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On GSK's Profit Performance
Unusual items (expenses) detracted from GSK's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that GSK's statutory profit actually understates its earnings potential! And on top of that, its earnings per share have grown at an extremely impressive rate over the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about GSK as a business, it's important to be aware of any risks it's facing. For example, we've discovered 3 warning signs that you should run your eye over to get a better picture of GSK.
Today we've zoomed in on a single data point to better understand the nature of GSK's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
View Comments
- Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation
May 5, 2026
VANCOUVER, BC / ACCESS Newswire / May 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Inka Health Corp. ("Inka Health"), the Company's wholly owned subsidiary, has started a collaborative research agreement (the "Agreement" or "Project" or "Work") with GlaxoSmithKline LLC ("GSK"). Under the Agreement, Inka Health and GSK intend to collaborate to develop real-world data-driven methodologies aimed at improving the transportability of oncology clinical trial results across broader patient populations, geographies, and healthcare settings, with a view to helping to make clinical evidence more relevant to real-world decision-making.
As part of the Project, Onco's wholly-owned subsidiary, Inka Health, will contribute its expertise in advanced analytics, including machine learning and causal inference methods, and work with GSK Epidemiology and RWE experts with the aim of helping to develop a conceptual and methodological framework for the use of real-world data to support the transportability of clinical trials. Work is expected to include a comprehensive literature review on transportability methodologies as well as the design of a structured evaluation framework and retrospective testing and validation using publicly available oncology datasets and use cases. The Project is also expected to contribute to jointly authored scientific manuscripts with contributors from both Inka Health and GSK.
"We are pleased to work with Inka Health on this important area of evidence generation. As the use of real-world data continues to evolve, there is growing interest in methodologies that can help evaluate how clinical trial findings may translate across broader patient populations and care settings. We believe this work can contribute to the ongoing scientific dialogue in oncology and support more rigorous approaches to understanding the applicability of clinical evidence in real-world contexts," said Rodrigo Refoios Camejo, Executive Director of RWE Science & Innovation at GSK.
The initiative is focused on addressing a significant challenge in oncology research, namely, how to better assess whether clinical trial findings can be applied across diverse real-world settings. For example, a treatment that shows positive results in a controlled clinical trial involving a relatively narrow patient group may perform differently in broader real-world populations with varying demographics, health conditions, and access to care. By using real-world data to evaluate factors that may influence outcomes, the work contemplated under the agreement is intended to support more consistent and meaningful interpretation of trial evidence across geographies and populations.
Story Continues
"From Onco's perspective, this Agreement reflects the kind of high-value scientific work we believe can help shape the future of oncology research. It speaks to the relevance of our capabilities in evidence generation and advanced analytics, which we see as part of the broader vision for SynoGraph and Onco's integrated approach to oncology innovation. Over time, we believe capabilities developed across this ecosystem can help inform smarter development pathways and support our broader objective of advancing IND-enabling activities," said Thomas O' O'Shaughnessy, CEO of Onco-Innovations.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, in relation to the Company's ability to pursue the research activities contemplated under the Agreement, to maintain contractual relations as necessary to complete the Work, and the anticipated results or benefits of the Work. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including, but not limited to: that the Company may not be able to complete any activities under the Agreement, including as a result of a lack of financial resources, the inability to retain key personnel, or otherwise; that the Company may not be able to maintain contractual relations necessary to complete the Work; and that the results of the Work may not result in the results or benefits anticipated. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
View Comments
- SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab Setback
May 4, 2026
Summit Therapeutics SMMT reported first-quarter 2026 loss per share of 24 cents, narrower than the Zacks Consensus Estimate of a loss of 33 cents. In the year-ago period, the company had incurred a loss of 9 cents per share.
The company currently lacks a marketed product in its portfolio. As a result, it did not record revenues in 2025.
More on SMMT’s Q1 Results
Research and development (R&D) expenses rose significantly to $132.6 million, reflecting a 159% year-over-year increase. General and administrative expenses surged 301% year over year to $62.6 million. The substantial growth in operating costs was primarily due to higher stock-based compensation and increased clinical study costs and expenses related to building the infrastructure to support the development of ivonescimab.
As of March 31, 2026, Summit Therapeutics had cash, cash equivalents and short-term investments worth $598.7 million compared with $713.4 million as of Dec. 31, 2025.
SMMT’s Pipeline Updates
The lead program in the company’s pipeline is ivonescimab, a dual PD-1/VEGF inhibitor being evaluated in multiple late-stage studies across different settings in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). SMMT is developing ivonescimab in collaboration with China-based Akeso. Ivonescimab is currently approved only in China for two distinct NSCLC indications.
In January, the FDA accepted its biologics license application (BLA), seeking approval for ivonescimab plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with third-generation EGFR-TKIs. The BLA filing was based on encouraging results from the phase III HARMONi study. The FDA decision is expected by Nov. 14, 2026.
Summit Therapeutics PLC Price, Consensus and EPS SurpriseSummit Therapeutics PLC Price, Consensus and EPS Surprise
Summit Therapeutics PLC price-consensus-eps-surprise-chart | Summit Therapeutics PLC Quote
The company is currently enrolling patients in three late-stage studies on ivonescimab — two in NSCLC (HARMONi-3 and HARMONi-7) and one in CRC (HARMONi-GI3).
HARMONi-3 is evaluating the drug against Merck’s MRK blockbuster PD-L1 drug Keytruda (pembrolizumab) as a first-line treatment for metastatic squamous or non-squamous NSCLC, while HARMONi-7 is evaluating ivonescimab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression.
In the HARMONi-3 study, under the revised design, squamous and non-squamous NSCLC cohorts are being analyzed separately, with progression-free survival (PFS) and overall survival as primary endpoints.
Story Continues
Summit Therapeutics had planned to perform an interim PFS analysis from one part of its HARMONi-3 study — the squamous patient group — in the second quarter of 2026. If the data from the interim analysis were strong, it would have allowed Summit to begin discussions with regulators, including the FDA, instead of waiting for the final planned analysis later in 2026.
However, an Independent Data Monitoring Committee (iDMC) reviewed the results of the interim analysis and recommended that the study should continue as planned, with the final PFS results still expected in the second half of 2026. The iDMC found no safety concerns. This eliminated hopes of an early regulatory path, which led the stock to fall 25% on Friday.
Year to date, shares of SMMT have lost 3.8% compared with the industry’s 2.1% decline.Zacks Investment Research
Image Source: Zacks Investment Research
Patient enrollment in the phase III HARMONi-GI3 study, evaluating the candidate in combination with chemotherapy against bevacizumab plus chemotherapy in first-line unresectable metastatic colorectal cancer, is ongoing.
In January 2026, Summit Therapeutics announced a collaboration with GSK plc GSK to evaluate ivonescimab in combination with risvutatug rezetecan, GSK’s novel investigational B7-H3-targeting antibody-drug conjugate, across multiple solid tumor settings, including small cell lung cancer. Each company will retain full rights to its respective products. Patient dosing is expected to commence in mid-2026.
SMMT’s Zacks Rank & Stock to Consider
Summit Therapeutics currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Castle Biosciences CSTL, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Castle Biosciences’ 2026 loss per share have narrowed from $1.42 to $1.40. Over the same period, loss per share estimates for 2027 have also narrowed from 79 cents to 78 cents. CSTL shares have lost 36.2% year to date.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 34.69%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report
Merck & Co., Inc. (MRK) : Free Stock Analysis Report
Summit Therapeutics PLC (SMMT) : Free Stock Analysis Report
Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
